<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the adult with unexplained neutropenia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the adult with unexplained neutropenia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the adult with unexplained neutropenia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy Berliner, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1875273819"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neutropenia refers to a decrease in circulating neutrophils, which for adults corresponds to &lt;1500 cells/microL in most clinical laboratories.</p><p>This topic discusses evaluation of the adult patient with unexplained neutropenia.</p><p>The following topics are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Approach to the patient with pancytopenia (see  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of neutropenia in children (see  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of neutropenia and fever (see  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of non-chemotherapy-induced neutropenia (see  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of drug-induced neutropenia (see  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a>)</p><p></p><p class="headingAnchor" id="H1006808"><span class="h1">DEFINITIONS AND NORMAL VALUES</span><span class="headingEndMark"> — </span>The normal range (ie, two standard deviations above and below the mean) for the white blood cell (WBC) count in adults is 4400 to 11,000 cells/microL (4.4 to 11 x 10<sup>9</sup> cells/L) in most clinical laboratories. (See <a class="local">'Epidemiology'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutrophils</strong> – Neutrophils are the most abundant WBCs in peripheral blood (typically 40 to 70 percent). The term neutrophil refers to the staining characteristics of the cytoplasmic granules; mature neutrophils are also called polymorphonuclear cells (PMNs) based on the characteristic segmentation of the nucleus (<a class="graphic graphic_picture graphicRef60666" href="/z/d/graphic/60666.html" rel="external">picture 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absolute neutrophil count </strong>–<strong> </strong>The absolute neutrophil count (ANC) is the number of neutrophils plus bands, but does not include metamyelocytes and less mature forms. </p><p></p><p class="bulletIndent2">ANC = WBC (cells/microL) x percent (PMNs  +  bands) ÷ 100 (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – Neutropenia is usually defined as an ANC &lt;1500 cells/microL in an adult. Some institutions use different values (eg, the World Health Organization uses ≤1800 cells/microL) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Neutropenia can be categorized as [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild </strong>– ANC ≥1000 and &lt;1500 cells/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate </strong>– ANC ≥500 and &lt;1000 cells/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe </strong>– ANC &lt;500 cells/microL </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agranulocytosis</strong> – ANC &lt;200 cells/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic neutropenia</strong> – Neutropenia for &gt;3 months [<a href="#rid2">2</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constitutional neutropenia</strong> – Longstanding neutropenia, typically since childhood</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulocytopenia</strong> – Reduced number of neutrophils, eosinophils, and basophils</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated neutropenia</strong> – Neutropenia without associated anemia and/or thrombocytopenia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukopenia</strong> – Reduced total WBC count (&lt;4400 cells/microL in most clinical laboratories)</p><p></p><p>Normal values for WBC and ANC count in children vary by age and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>.)</p><p class="headingAnchor" id="H1006814"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of neutropenia in normal adults varies by the population studied due, in part, to different normal values for white blood cell/absolute neutrophil count in certain ethnic groups.</p><p>The prevalence of neutropenia is reported from 0 to 10 percent in healthy, asymptomatic individuals, but is higher in individuals with certain medical conditions (eg, autoimmune/connective tissue diseases), as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia was reported in 1 percent of &gt;370,000 routine complete blood counts (CBCs) in Denmark [<a href="#rid3">3</a>]. Chronic neutropenia (from repeat CBCs &gt;3 months apart) was reported in 0.1 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A United States study that included &gt;25,000 individuals reported the following rates of prevalence [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Black Americans – 4.5 percent</p><p class="bulletIndent2"><span class="glyph">•</span>White Americans – 0.79 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Mexican Americans – 0.38 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 261 healthy women in New York City, prevalence varied by country of origin (self-identified) [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>United States (Black participants) – 10.5 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Haiti – 8.2 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Barbados/Trinidad and Tobago – 6.4 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Jamaica – 2.7 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Dominican Republic – 0 percent</p><p class="bulletIndent2"><span class="glyph">•</span>United States or European (White participants) – 0 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia is more common in certain rheumatologic disorders (eg, rheumatoid arthritis, systemic lupus erythematosus), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7512.html" rel="external">"Hematologic complications of rheumatoid arthritis", section on 'Neutropenia'</a> and  <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">"Hematologic manifestations of systemic lupus erythematosus", section on 'Neutropenia'</a>.)</p><p></p><p>The prevalence of neutropenia in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents", section on 'Normal variants'</a>.)</p><p class="headingAnchor" id="H1006820"><span class="h1">MECHANISMS</span><span class="headingEndMark"> — </span>Neutrophils are produced in the bone marrow and migrate to the circulation, vascular endothelium, spleen, and sites of infection/inflammation. The normal processes of neutrophil production and differentiation are described separately. (See  <a class="medical medical_review" href="/z/d/html/8380.html" rel="external">"Regulation of myelopoiesis", section on 'Neutrophil production and maturation'</a>.)</p><p>Neutropenia can result from three basic mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased neutrophil production/differentiation in bone marrow (eg, drug-associated, infection, nutritional deficiency)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Redistribution of circulating neutrophils to the vascular endothelium or to the spleen (termed "margination")</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune destruction (eg, drug reaction, autoimmunity)</p><p></p><p class="headingAnchor" id="H1006826"><span class="h1">CAUSES OF NEUTROPENIA</span><span class="headingEndMark"> — </span>Neutropenia in adults can be caused by inherited/congenital disorders or acquired conditions.</p><p>The causes of neutropenia vary with the population and clinical setting. As an example, the causes of neutropenia in hospitalized patients differ from those of ambulatory adults. (See <a class="local">'Other scenarios'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duffy-null associated neutrophil count</strong> – Duffy-null associated neutrophil count (DANC; formerly called benign ethnic neutropenia) is an inherited cause of mild/moderate neutropenia in individuals of African descent and certain other ethnic groups that is not associated with increased infections. There is an effort to move away from the designation "benign ethnic neutropenia" because it implies an abnormality when it is in fact a normal variant. The clinical presentation, pathophysiology, and diagnosis of DANC are discussed below. (See <a class="local">'Normal variants &lt;1500/microL'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial neutropenia</strong> – Familial neutropenia refers to unexplained mild neutropenia in families from ethnic groups that are not typically associated with DANC. (See <a class="local">'Normal variants &lt;1500/microL'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital neutropenia </strong>–<strong> </strong>Congenital neutropenia syndromes are occasionally first detected in adults, but they are usually recognized during childhood because of associated infections or somatic findings (eg, premature graying of the hair, abnormalities of fingernails or skeleton), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Neutropenia can be seen with viral (eg, hepatitis, human immunodeficiency virus [HIV], Epstein-Barr virus [EBV]), bacterial, parasitic, and rickettsial infections. Infectious causes of neutropenia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8372.html" rel="external">"Infectious causes of neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Predictable, dose-dependent effects of cytotoxic or immunosuppressive agents are the most common reason for medication-associated neutropenia. Such neutropenia is usually associated with thrombocytopenia and/or anemia, and these effects are generally reversible if the suspected agent is reduced or stopped. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Suspected medications'</a>.)</p><p></p><p class="bulletIndent1">Some other anti-cancer agents (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, tyrosine kinase inhibitors) that are not considered myelosuppressive are occasionally associated with isolated neutropenia, as described separately. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Myelosuppression'</a>.)</p><p></p><p class="bulletIndent1">Many medications have been associated with severe idiosyncratic isolated neutropenia (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 1</a>), which typically occurs within three months of starting a new drug. Drug-induced neutropenia is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Drug-induced neutropenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional</strong> – Deficiencies of dietary vitamins and minerals (eg, vitamin B12, folate, copper) typically cause neutropenia in association with other cytopenias, but isolated or predominant neutropenia is possible, as discussed separately (See  <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Copper'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic malignancies</strong> – Large granular lymphocyte (LGL) leukemia, hairy cell leukemia, other lymphoproliferative disorders, myelodysplastic syndromes, or other hematologic malignancies occasionally present with isolated neutropenia, but they are more typically manifest as pancytopenia, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16360.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia", section on 'Peripheral blood'</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Complete blood count'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatologic disorders</strong> – Rheumatoid arthritis, systemic lupus erythematosus, and other rheumatologic disorders may be associated with neutropenia, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7512.html" rel="external">"Hematologic complications of rheumatoid arthritis", section on 'Neutropenia'</a> and  <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">"Hematologic manifestations of systemic lupus erythematosus", section on 'Neutropenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune neutropenia</strong> – Autoimmune neutropenia may occur alone (primary autoimmune neutropenia) or in association with other conditions, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8371.html" rel="external">"Immune neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aplastic anemia</strong> – Neutropenia may be the initial or predominant manifestation, but aplastic anemia is typically manifest as pancytopenia, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic idiopathic neutropenia</strong> – Chronic idiopathic neutropenia (CIN) is characterized by longstanding neutropenia without an obvious cause. The clinical presentation of CIN in adulthood is variable, ranging from an asymptomatic, incidental finding to aphthous ulcers, gingivitis, and frequent infections. Diagnosis and management of CIN are described separately. (See  <a class="medical medical_review" href="/z/d/html/8371.html" rel="external">"Immune neutropenia", section on 'Chronic idiopathic neutropenia'</a>.)</p><p></p><p>Causes of neutropenia in the setting of pancytopenia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>.)</p><p class="headingAnchor" id="H1006856"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>Neutropenia may be encountered in the course of evaluating other clinical findings or as an incidental abnormality on a complete blood count (CBC) and differential.</p><p>Evaluation of neutropenia should include prompt assessment for potential medical emergencies and determination of the cause of neutropenia, as described in the sections below.</p><p>Initial evaluation includes CBC and differential, history and physical examination, and review of the blood smear. In some circumstances, other laboratory tests may be performed as part of the initial evaluation, as described below. (See <a class="local">'Other initial laboratory testing'</a> below.)</p><p class="headingAnchor" id="H2250762907"><span class="h2">Urgency of evaluation</span><span class="headingEndMark"> — </span>The urgency of evaluation of neutropenia is guided by the patient's clinical condition, severity of neutropenia, and the presence of worrisome findings on the blood smear.</p><p>Management of infections and other emergency conditions should not be delayed by evaluation of the cause of neutropenia.</p><p>Our approach follows:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients, regardless of the level of absolute neutrophil count (ANC), with findings of sepsis, hemodynamic instability, respiratory compromise, or other clinical emergencies require immediate hospitalization and urgent evaluation. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Emergencies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ANC &lt;500 cells/microL or worrisome findings on blood smear (eg, leukemic blasts, schistocytes) should be evaluated immediately and often require hospitalization. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Worrisome findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic patients with moderate neutropenia (ie, ≥500 to &lt;1000 neutrophils/microL) and no worrisome findings on blood smear should have a repeat CBC and differential count within one to two weeks, followed by outpatient evaluation if neutropenia persists.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic patients with ANC &gt;1000 cells/microL and no worrisome findings on blood smear should have repeat CBC/differential within two to six weeks, followed by outpatient evaluation if neutropenia persists.</p><p></p><p class="headingAnchor" id="H286554930"><span class="h2">Complete blood count (CBC)</span><span class="headingEndMark"> — </span>CBC with differential count should be repeated to confirm the level of ANC, with the urgency of repeat testing informed by the criteria described above. (See <a class="local">'Urgency of evaluation'</a> above.)</p><p>When available, prior CBCs (both normal and abnormal) can provide important information about the duration and trajectory of neutropenia.</p><p>Isolated severe neutropenia (ie, &lt;500 cells/microL) is most commonly due to medications; sepsis and viral infections may also cause isolated neutropenia, but it is seldom severe. Rarely, severe neutropenia is caused by a congenital neutropenia syndrome that was not identified in childhood. (See <a class="local">'Causes of neutropenia'</a> above.)</p><p>The most common causes of isolated mild neutropenia in adults are Duffy-null associated neutrophil count (DANC), dose-dependent drug-induced neutropenia (eg, cytotoxic agents), and infections (usually viral). Other common causes of mild neutropenia include nutritional deficiencies, rheumatologic disorders, and hematologic conditions (eg, myelodysplasia).</p><p>Neutropenia may be the only hematologic abnormality or it may be accompanied by other findings including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilia and/or basophilia</strong> that may be associated with drug reaction/allergy, infection (especially parasitic), or cancer (eg, eosinophilic leukemia, other acute leukemia, solid tumor) (<a class="graphic graphic_table graphicRef76434" href="/z/d/graphic/76434.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytes </strong>(see  <a class="medical medical_review" href="/z/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocytosis (eg, large granular lymphocyte [LGL] leukemia, chronic lymphocytic leukemia [CLL], acute lymphoblastic leukemia, lymphomas) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphopenia (eg, immunodeficiency)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong>: Anemia associated with neutropenia can have varied causes. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemolytic anemia (eg, disseminated intravascular coagulation [DIC], thrombotic thrombocytopenic purpura [TTP], paroxysmal nocturnal hemoglobinuria [PNH]) (see  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a> and  <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia of chronic disease (eg, rheumatologic disorders, cancers, chronic infections) (see  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Macrocytic anemia may be due to megaloblastic disorders (eg, deficiency of vitamin B12 or folate) or reticulocytosis (eg, hemolytic anemia, recovery from bone marrow suppression) (see  <a class="medical medical_review" href="/z/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Causes of macrocytosis/macrocytic anemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aplastic anemia (see  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myelophthisic disorders (bone marrow infiltration by fibrosis, malignancy, or infection) (see  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Leukoerythroblastic smear'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet abnormalities</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytopenia (eg, DIC, autoimmunity) (see  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytosis (eg, infection, inflammatory conditions) (see  <a class="medical medical_review" href="/z/d/html/6682.html" rel="external">"Approach to the patient with thrombocytosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancytopenia</strong> – Evaluation of pancytopenia (ie, neutropenia accompanied by both anemia and thrombocytopenia) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>.)</p><p></p><p class="headingAnchor" id="H2255541109"><span class="h2">History</span><span class="headingEndMark"> — </span>The history should seek evidence of disorders that might account for neutropenia. (See <a class="local">'Causes of neutropenia'</a> above.)</p><p>Important aspects of the history include evidence of:</p><p class="bulletIndent1"><span class="glyph">●</span>Active or prior infection or inflammatory processes (eg, trauma, rheumatologic disorders)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodic aphthous ulcers and/or infections (eg, a periodicity of two to three weeks may suggest cyclic neutropenia) (see  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previously diagnosed hematologic malignancy (eg, lymphoma, leukemia), other cancers, or related clinical findings (eg, unexplained lymphadenopathy, fevers, sweats, weight loss)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal disorders (eg, inflammatory bowel disease or bariatric surgery may impair absorption of vitamin B12, folate, or copper) or liver disease (eg, associated with infections, rheumatologic conditions, or hematologic malignancies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections (eg, hepatitis, human immunodeficiency virus [HIV], Epstein-Barr virus [EBV], intestinal parasites)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications – The relationship between the onset of neutropenia and administration of medications should be determined (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 1</a>) (see <a class="local">'Causes of neutropenia'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personal and occupational exposures – Diet (eg, long-standing veganism may be associated with dietary deficiency of vitamin B12), excessive alcohol consumption (which may be associated with folate deficiency), exposure to toxic agents at work or home (eg, organic solvents), and travel history (eg, exposure to malaria, leishmania)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of neutropenia, bone marrow failure syndromes, other hematologic disorders, skeletal abnormalities, or early childhood deaths may suggest a congenital neutropenia syndrome (see  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethnicity – Ethnicity/national origin from a region associated with Duffy-associated neutrophil count (DANC) (see <a class="local">'Normal variants &lt;1500/microL'</a> below)</p><p></p><p class="headingAnchor" id="H2438170411"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Classic findings of infection may be less apparent in a patient with severe neutropenia, due to the lack of pus and/or signs of inflammation, both of which require adequate neutrophils.</p><p>Physical examination may reveal:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin erythema, ulcerations, fissures, and tenderness, especially at sites of indwelling catheters and the perirectal/genital areas</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gingivitis, swelling, oral ulceration, or dental pain </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal respiratory exam</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Findings that may help to determine the cause of the neutropenia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Jaundice or other stigmata of liver disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Joint swelling or bone pain may suggest a rheumatologic disorder, infection, or malignancy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rash may suggest a rheumatologic disorder or drug allergy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphadenopathy (<a class="graphic graphic_table graphicRef109481" href="/z/d/graphic/109481.html" rel="external">table 3</a>) or splenomegaly (<a class="graphic graphic_table graphicRef69397" href="/z/d/graphic/69397.html" rel="external">table 4</a>) may suggest hematologic malignancy or other cancer, rheumatologic disorders, or infection (see  <a class="medical medical_review" href="/z/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuro/psychiatric abnormalities may suggest a nutritional deficiency (eg, vitamin B12, copper), alcoholism, or HIV infection</p><p></p><p class="headingAnchor" id="H2504697407"><span class="h2">Peripheral blood smear</span><span class="headingEndMark"> — </span>The peripheral blood smear should assess neutrophil morphology and detect other hematologic findings. </p><p></p><p>Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutrophils </strong>(see  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Neutrophil series'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Toxic granulations or Dohle bodies (<a class="graphic graphic_picture graphicRef70248" href="/z/d/graphic/70248.html" rel="external">picture 2</a>) associated with sepsis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bilobed (<a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">picture 3</a>) or dysplastic neutrophils (<a class="graphic graphic_picture graphicRef85881" href="/z/d/graphic/85881.html" rel="external">picture 4</a>) due to myelodysplastic syndromes (MDS) or congenital disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypersegmented neutrophils (<a class="graphic graphic_picture graphicRef70609" href="/z/d/graphic/70609.html" rel="external">picture 5</a>) due to megaloblastic disorders (eg, vitamin B12 or folate deficiency)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immature myeloid cells without mature neutrophils due to acute myeloid leukemia (<a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">picture 6</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytes</strong> (see  <a class="medical medical_review" href="/z/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia", section on 'Peripheral blood smear'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atypical lymphocytes (<a class="graphic graphic_picture graphicRef55986" href="/z/d/graphic/55986.html" rel="external">picture 7</a>) suggest a viral cause (eg, EBV, cytomegalovirus [CMV])</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Smudge" lymphocytes (<a class="graphic graphic_picture graphicRef54469" href="/z/d/graphic/54469.html" rel="external">picture 8</a>) are characteristic of CLL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Hair-like" projections on lymphocytes (<a class="graphic graphic_picture graphicRef102936" href="/z/d/graphic/102936.html" rel="external">picture 9</a>) are seen in hairy cell leukemia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocytes with azurophilic granules (<a class="graphic graphic_picture graphicRef69027" href="/z/d/graphic/69027.html" rel="external">picture 10</a>) may be seen in LGL leukemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Red blood cells </strong>(see  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Red blood cells'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Macro-ovalocytes (<a class="graphic graphic_picture graphicRef74901" href="/z/d/graphic/74901.html" rel="external">picture 11</a>) associated with megaloblastic anemias</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fragmented cells from microangiopathy (eg, DIC)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tear drop-shaped cells (<a class="graphic graphic_picture graphicRef55274" href="/z/d/graphic/55274.html" rel="external">picture 12</a>) associated with myelophthisic processes (eg, primary myelofibrosis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spiculated (<a class="graphic graphic_picture graphicRef120809" href="/z/d/graphic/120809.html" rel="external">picture 13</a>) or target cells (<a class="graphic graphic_picture graphicRef80318" href="/z/d/graphic/80318.html" rel="external">picture 14</a>) that may be due to liver disease</p><p></p><p class="headingAnchor" id="H1787778185"><span class="h2">Other initial laboratory testing</span><span class="headingEndMark"> — </span>Other laboratory studies may provide important data for defining the cause or assessing complications of neutropenia.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The following tests should be performed for incidentally discovered neutropenia, clinical evidence of liver disease, or blood smears that demonstrate macrocytosis, spiculated or target red blood cells, hypersegmented neutrophils, and/or atypical lymphocytes (see <a class="local">'Peripheral blood smear'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin B12, folate, and copper levels</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests and screening for viral hepatitis and HIV infection (if not recently evaluated) (see  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a> and  <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV", section on 'Initial laboratory testing'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation testing (eg, prothrombin time, partial thromboplastin time, D-dimer), lactate dehydrogenase (LDH), and serum creatinine should be performed for febrile or hemodynamically unstable patients who may have sepsis and/or DIC, or fragmented red blood cells on the blood smear. (See  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation and management of fever or suspected infection with neutropenia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1">For patients with suspected infections, we suggest <strong>not</strong> performing routine serologic screening for infectious causes of neutropenia, other than hepatitis, EBV, and HIV, as described above, unless it is otherwise clinically important (eg, CMV, toxoplasma infections in a pregnant woman). (See  <a class="medical medical_review" href="/z/d/html/6011.html" rel="external">"Overview of TORCH infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) may be useful in a patient with moderate/severe neutropenia (eg, &lt;1000 cells/microL), since classic findings of infection or inflammation may be subtle or inapparent. (See  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Monitoring response to treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood typing for Duffy antigen is suggested by some experts to support a diagnosis of Duffy-null associated neutrophil count. (See <a class="local">'Normal variants &lt;1500/microL'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest <strong>not</strong> performing screening studies for rheumatologic disorders (eg, anti-nuclear antibody, anti-DNA antibody, complement levels) in the absence of clinical findings associated with such disorders (eg, arthritis, serositis). (See <a class="local">'Rheumatologic/Autoimmune disorders'</a> below.)</p><p></p><p class="headingAnchor" id="H2263644538"><span class="h1">SUBSEQUENT EVALUATION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Our approach is guided by whether findings from the initial evaluation lead to identification of a clear cause for neutropenia, as described below.</p><p>Often, more than one possible cause of neutropenia is identified by the initial evaluation. As examples, repletion of vitamin deficiencies or discontinuing/reducing other contributing factors (eg, medications, alcohol) may lessen the degree of neutropenia and clarify the diagnostic possibilities.</p><p>Evaluation of specific causes of neutropenia is described in the sections below.</p><p>Management of medical emergencies must take place even as the diagnostic evaluation is proceeding. As examples, treatment of sepsis or the complications of acute leukemia must be addressed immediately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Emergencies'</a>.)</p><p>The urgency of evaluation and, in some cases, the need for hospitalization is described above. (See <a class="local">'Urgency of evaluation'</a> above.)</p><p class="headingAnchor" id="H1337570293"><span class="h2">Diagnosis established by initial evaluation</span><span class="headingEndMark"> — </span>For the following diagnoses that may be defined by the initial evaluation, no further testing or follow up is required if one or two subsequent complete blood counts (CBCs) reveal that the absolute neutrophil count (ANC) responded as expected.</p><p>If the ANC does not reveal the expected response or if the ANC declines, further evaluation is appropriate, as described in the sections below.</p><p class="headingAnchor" id="H2153946850"><span class="h3">Nutritional deficiency</span><span class="headingEndMark"> — </span>Repletion of vitamin B12, folate, or copper should cause a predictable improvement in hematologic parameters; evaluation and management of an inadequate response is described separately. Neutropenia should improve within days but may take two to four weeks to resolve; hypersegmented neutrophils may persist for up to four weeks. (See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/16517.html" rel="external">"Copper deficiency myeloneuropathy", section on 'Diagnosis and evaluation'</a>.)</p><p class="headingAnchor" id="H1463070197"><span class="h3">Viral infection</span><span class="headingEndMark"> — </span>Acute viral infections may cause transient, mild neutropenia that should improve within one to two weeks. Recovery of ANC may be slower with human immunodeficiency virus (HIV) and hepatitis infections, as described separately. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a> and  <a class="medical medical_review" href="/z/d/html/6679.html" rel="external">"HIV-associated cytopenias", section on 'Neutropenia'</a>.)</p><p>If recovery from an apparent viral infection is significantly delayed or incomplete, other causes of neutropenia (eg, medications, inherited/congenital disorders) should be considered and referral to hematology may be helpful. (See <a class="local">'Hematology referral'</a> below.)</p><p class="headingAnchor" id="H192736085"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Management of medications that may contribute to neutropenia is guided by the ANC:</p><p class="bulletIndent1"><span class="glyph">●</span>If the ANC is &lt;1000 cells/microL, all drugs that are associated with idiosyncratic reactions (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 1</a>) should be discontinued immediately, if clinically feasible, and cytotoxic/immunosuppressive drugs should be withheld. Critical medications (eg, some psychotropic or antiseizure medications) for which no suitable alternative is available, may be continued unless the ANC falls &lt;500 cells/microL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild neutropenia (ie, ≥1000 cells/microL) is less likely to represent an idiosyncratic drug reaction. Cytotoxic/immunosuppressive drugs should be withheld until the neutropenia improves, but it is <strong>not</strong> necessary to discontinue all other suspect critical medications (eg, psychotropic or antiseizure medications).</p><p></p><p>Neutropenia caused by bone marrow suppression due to cytotoxic or immunosuppressive drugs should improve within two to three weeks of the last treatment. Delayed recovery or worsening of neutropenia may suggest other contributing causes (eg, concurrent viral suppression, treatment-associated hematologic disorder) and may benefit from referral to a hematologist for bone marrow evaluation. (See <a class="local">'Hematology referral'</a> below.)</p><p class="headingAnchor" id="H597456247"><span class="h2">Other scenarios</span><span class="headingEndMark"> — </span>For conditions that are not explained by the initial evaluation, further testing is guided by the clinical setting, as described below.</p><p class="headingAnchor" id="H3938224043"><span class="h3">Hospitalized patient</span><span class="headingEndMark"> — </span>The hospitalized patient with neutropenia should be promptly assessed for potential medical emergencies and managed accordingly. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Emergencies'</a>.)</p><p>Evaluation of neutropenia in the hospitalized patient should determine, when possible, whether neutropenia developed during the hospitalization or was present previously. Results of CBCs/differential counts from prior hospitalizations and the ambulatory setting are important for making this distinction.</p><p>For neutropenia that developed while hospitalized, the ANC should be correlated with all medications, including drugs that have predictable marrow suppressive activity and those associated with idiosyncratic neutropenia (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 1</a>). Management of medications that may contribute to neutropenia is described above. (See <a class="local">'Medications'</a> above.)</p><p>For patients whose ANC does not improve in the face of the medication adjustments described above, and for neutropenia that remains otherwise unexplained, referral to hematology and/or bone marrow evaluation may be useful, especially if there is suspicion for an underlying hematologic malignancy (eg, lymphadenopathy, splenomegaly, leukoerythroblastic blood smear) or chronic infection (eg, fungal or mycobacterial). (See <a class="local">'Hematology referral'</a> below.)</p><p>Other aspects of management of drug-associated neutropenia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1315143930"><span class="h3">Asymptomatic incidental neutropenia</span><span class="headingEndMark"> — </span>Laboratory testing and management of medications for the patient with incidentally detected, asymptomatic neutropenia is described above. (See <a class="local">'Other initial laboratory testing'</a> above and <a class="local">'Medications'</a> above.)</p><p>Our approach is informed by the level and trajectory of the ANC, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For an asymptomatic patient with ANC ≥1000 cells/microL, the initial evaluation can be performed as an outpatient.</p><p></p><p class="bulletIndent1">If the ANC improves over days to weeks, the most likely diagnoses are transient neutropenia from a viral syndrome or myelosuppressive medication. No further testing is required and suggestions for monitoring are described below. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1">For a stable pattern of mild neutropenia, the most likely diagnoses are Duffy-null associated neutrophil count, familial neutropenia, autoimmune neutropenia, rheumatologic conditions, hematologic malignancies (eg, low grade lymphoma), or nutritional deficiencies, as described above. (See <a class="local">'Causes of neutropenia'</a> above and <a class="local">'Normal variants &lt;1500/microL'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with ANC &lt;1000 cells/microL, worsening neutropenia, or those who become symptomatic, the urgency and setting of evaluation and management (ie, outpatient versus hospital) is described above. (See <a class="local">'Urgency of evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H2675599760"><span class="h3">Abnormal blood smear/CBC</span><span class="headingEndMark"> — </span>Further evaluation is informed by the nature of abnormalities on the blood smear:</p><p class="bulletIndent1"><span class="glyph">●</span>Findings that suggest acute leukemia or other aggressive hematologic malignancy (eg, leukemic blasts, maturation arrest, myelophthisic changes) should be evaluated immediately with hospitalization and urgent referral to hematology, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Worrisome findings'</a> and  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Emergencies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Schistocytes or other findings that suggest disseminated intravascular coagulation (DIC) warrant immediate hospitalization and emergency management, as described separately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Emergencies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophils with toxic granulations and/or Dohle bodies suggest acute infection and/or sepsis, and should be evaluated urgently, as described below. (See <a class="local">'Infection/Fever'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysplastic granulocytes, aberrant lymphoid cells (eg, hairy cells, smudge cells, large granular lymphocytes), and other findings that suggest an underlying hematologic malignancy should lead to prompt hematology referral and further evaluation, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Worrisome findings'</a> and <a class="local">'Hematology referral'</a> below.)</p><p></p><p class="headingAnchor" id="H247857975"><span class="h3">Infection/Fever</span><span class="headingEndMark"> — </span>Patients with neutropenia and findings of sepsis, hemodynamic instability, respiratory compromise, or other clinical emergencies require immediate hospitalization and urgent evaluation. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Emergencies'</a> and  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Treatment of infection'</a>.)</p><p>Oral temperature ≥38.0°C (&gt;100.4°F) should be assumed to be due to infection and requires prompt antibiotic therapy, whether the fever/infection is thought to be the cause of neutropenia (eg, viral infection) or a result of neutropenia (especially bacterial infections). Urgent evaluation and management of fever with neutropenia is described separately. (See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1186637935"><span class="h3">Rheumatologic/Autoimmune disorders</span><span class="headingEndMark"> — </span>Neutropenia is often encountered in the setting of rheumatologic disorders (eg, systemic lupus erythematosus, rheumatoid arthritis) and establishing a clear cause for neutropenia may be challenging.</p><p>Evaluation of hematologic manifestations of rheumatologic conditions is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7512.html" rel="external">"Hematologic complications of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">"Hematologic manifestations of systemic lupus erythematosus", section on 'Neutropenia'</a>.) </p><p class="headingAnchor" id="H3322375880"><span class="h3">Suspected congenital neutropenia</span><span class="headingEndMark"> — </span>Congenital neutropenia should be considered in adults with unexplained, severe neutropenia (&lt;500 cells/microL) in the setting of somatic findings (eg, pancreatic dysfunction, premature graying of the hair, abnormalities of fingernails or skeleton), or a family history of neutropenia, unexplained childhood deaths, or somatic syndromes. Examples of congenital syndromes that may present with neutropenia in adulthood are cyclic neutropenia, Shwachman-Diamond syndrome, Fanconi anemia, dyskeratosis congenita, and others [<a href="#rid6">6</a>]. The patient with a suspected congenital neutropenia syndrome should be referred to a hematologist who has expertise in these disorders, and the diagnosis is established by a bone marrow biopsy with genetic testing, as described separately. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p>Cyclic neutropenia should also be considered in patients with an episodic pattern of recurrent aphthous ulcers or infections with a two- to four-week periodicity. To demonstrate a pattern of cyclic neutropenia, CBCs/differentials should be obtained two times per week for six weeks, as described separately. (See  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>.) </p><p class="headingAnchor" id="H3348587662"><span class="h2">Normal variants &lt;1500/microL</span><span class="headingEndMark"> — </span>Some individuals have an ANC &lt;1500/microL with no recurrent or severe infections, other cytopenias, or associated illnesses [<a href="#rid7">7</a>]. Most commonly, this inherited condition is associated with the Duffy null [Fy(a-b-)] red blood cell phenotype (which is protective against malaria), but other causes have been identified.</p><p>These variants are most often encountered in individuals of African descent and in Sephardic Jews, West Indians, Yemenites, Greeks, and Arabs. This condition may also be called constitutional neutropenia and was formerly described as "benign ethnic neutropenia," but the preferred designation is "Duffy-null associated neutrophil count (DANC)."</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Constitutional neutropenia is not associated with recurrent or unusual infections, other cytopenias, physical findings, or other causes of cytopenias (eg, medications, excessive alcohol consumption, liver disease, autoimmune conditions). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duffy null [Fy(a-b-)] phenotype</strong> – Homozygosity for <em>rs2814778</em>, a single nucleotide polymorphism (SNP) of the <em>ACKR1</em> gene, is most commonly associated; this SNP is the predominant <em>ACKR1</em> allele in Black individuals, yet neutropenia is manifest in only a subset of individuals who are homozygous for <em>rs2814778</em> [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>CXCL2/CXCR2</em></strong><em> </em>–<em> </em>The rs9131 SNP of the chemokine, <em>CXCL2</em>, has been associated with lower levels of ANC [<a href="#rid9">9</a>]; rare variants of the receptor, CXCR2, are also associated with lower neutrophil counts [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>TCIRG1</em></strong> – Rare variants of <em>TCIRG1</em> (eg, rs587779413) may be associated with low ANC; homozygous or compound mutations of <em>TCIRG1</em> may cause osteopetrosis [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The ANC is typically &gt;1200 cells/microL, but it may occasionally be &lt;1000 cells/microL. The blood smear is normal. </p><p></p><p class="bulletIndent1">The diagnosis is based on persistent ANC &lt;1500/microL in an individual with no history of abnormal infections and no findings from the history, physical examination, or laboratory studies that suggest an alternative explanation for neutropenia. In practice, we generally repeat the CBC two or three times, separated by intervals of at one month. Detection of homozygosity for <em>ACKR1</em> <em>rs2814778 </em>or the Duffy null [Fy(a-b-)] phenotype supports, but is not required for the diagnosis of constitutional neutropenia. Bone marrow examination is not required for diagnosis, but it should be performed if there is substantial concern for an alternative diagnosis (eg, inherited and acquired causes for neutropenia).</p><p></p><p class="headingAnchor" id="H3020021778"><span class="h1">FURTHER EVALUATION</span><span class="headingEndMark"> — </span>Referral to hematology and/or specialized testing may be useful for patients in whom the cause for neutropenia has not been established by the initial evaluation.</p><p class="headingAnchor" id="H1962910653"><span class="h2">Hematology referral</span><span class="headingEndMark"> — </span>Most patients with neutropenia do not require referral to a hematologist. For patients with mild, asymptomatic neutropenia that is explained by the initial evaluation, the diagnosis, management, and monitoring can be performed by the primary clinician. (See <a class="local">'Diagnosis established by initial evaluation'</a> above.)</p><p>Examples of situations that warrant referral to hematology include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate referral</strong> (within hours):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Leukemic blasts or other worrisome findings on the blood smear that suggest acute leukemia (see <a class="local">'Abnormal blood smear/CBC'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Agranulocytosis (ANC &lt;200 cells/microL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prompt referral</strong> (within days):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other abnormalities on blood smear that suggest a hematologic malignancy (eg, dysplastic granulocytes, tear drop red blood cells, "hairy" lymphocytes, "smudge" cells, large granular lymphocytes), or related clinical findings (eg, unexplained lymphadenopathy, splenomegaly) (see <a class="local">'Peripheral blood smear'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of or progression to pancytopenia (see  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Subsequent evaluation'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Characteristic physical findings or family history of congenital neutropenia syndrome (see <a class="local">'Suspected congenital neutropenia'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timely referral</strong> (days to weeks):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Worsening of neutropenia or persistence of ANC &lt;1000 cells/microL that is not due to Duffy-null associated neutrophil count, rheumatologic disorder, or hypersplenism (eg, due to liver cirrhosis) (see <a class="local">'Diagnosis established by initial evaluation'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inadequate response to treatment of a nutritional deficiency that is not accounted for by poor compliance or malabsorption, as described separately (see  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies", section on 'Approach to lack of response'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pattern of episodic infections and/or aphthous ulcers that is consistent with cyclic neutropenia (see  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>)</p><p></p><p class="headingAnchor" id="H1862779483"><span class="h2">Bone marrow examination</span><span class="headingEndMark"> — </span>Bone marrow aspirate and biopsy is useful in a minority of patients with neutropenia. (See  <a class="medical medical_review" href="/z/d/html/4436.html" rel="external">"Bone marrow aspiration and biopsy: Indications and technique", section on 'Indications'</a>.)</p><p>The urgency for performing a bone marrow biopsy is influenced by the likely cause(s) of neutropenia, severity and trajectory of ANC, clinical stability, medical complications, and the urgency for evaluation and management. (See <a class="local">'Urgency of evaluation'</a> above.)</p><p>Bone marrow specimens provide information regarding abundance, maturation, and morphology of neutrophils; and other normal cellular elements; infiltrative disorders (eg, fibrosis, lymphoma, leukemia, metastatic cancer, fungal or mycobacterial infection); and provides material for microbiology culture, flow cytometry, and cytogenetic/molecular studies. (See  <a class="medical medical_review" href="/z/d/html/4436.html" rel="external">"Bone marrow aspiration and biopsy: Indications and technique", section on 'Indications'</a>.)</p><p>In general, bone marrow examination for evaluation of neutropenia is:</p><p class="bulletIndent1"><span class="glyph">●</span>Essential when a primary hematologic disorder (eg, acute leukemia, myelodysplastic syndrome, aplastic anemia) or congenital neutropenia syndrome is suspected. (See <a class="local">'Abnormal blood smear/CBC'</a> above and <a class="local">'Suspected congenital neutropenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May be useful when a diagnosis of fungal infection or tuberculosis is suspected. (See  <a class="medical medical_review" href="/z/d/html/8372.html" rel="external">"Infectious causes of neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May be useful when neutropenia responds inadequately after appropriate management (eg, after exclusion of noncompliance of malabsorption after repletion of vitamin B12 or folate). (See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies", section on 'Approach to lack of response'</a>.)</p><p></p><p>Bone marrow evaluation is usually uninformative for Duffy-null associated neutrophil count, drug-induced or autoimmune destruction, and viral or bacterial infections.</p><p>In some circumstances a bone marrow biopsy may be unhelpful or even distracting and confounding. As an example, a bone marrow biopsy performed just days after discontinuation of a suspect medication may show a "maturation arrest" (ie, recovery of bone marrow cells only up to an immature stage of differentiation) that may be morphologically indistinguishable from acute leukemia. Similarly, recent treatment with recombinant hematopoietic growth factors may induce a bone marrow morphology that is indistinguishable from certain myeloproliferative neoplasms or inflammatory conditions. In such situations it may be preferable to delay the biopsy by days to weeks.</p><p class="headingAnchor" id="H114947112"><span class="h1">RISK OF INFECTION</span><span class="headingEndMark"> — </span>The risk of infection is influenced by the severity and trajectory of the absolute neutrophil count (ANC). Stratification for infectious risk is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Infectious risk stratification'</a>.)</p><p>The underlying cause of neutropenia also affects the risk of infection. Conditions that are associated with impaired neutrophil production (eg, congenital neutropenia syndromes, nutritional deficiencies, aplastic anemia, myelodysplastic syndromes) are more likely to be associated with infections than those caused by other mechanisms (eg, Duffy-null associated neutrophil count, immune neutropenia), which generally have adequate bone marrow neutrophil reserves. (See <a class="local">'Mechanisms'</a> above.)</p><p>Patients who are neutropenic without fever or other evidence of infection are probably safer outside of a hospital than in a hospital. In contrast, most patients with fever and neutropenia require urgent hospital admission, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Overview of treatment'</a>.)</p><p>Counseling the patient and family regarding risk and management of infections is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Overview of treatment'</a> and  <a class="medical medical_review" href="/z/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Counseling regarding infectious risk'</a>.)</p><p class="headingAnchor" id="H1006967"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>The frequency and nature of follow-up for neutropenia is guided by the severity and trajectory of the absolute neutrophil count (ANC), the underlying diagnosis, response to interventions, the presence of associated symptoms and/or complications, and concern of the clinician and patient.</p><p>It is important to balance the need for periodic re-evaluation with the avoidance of unnecessary worry in an otherwise healthy individual. The cause of neutropenia should be explained to the patient to avoid exposure to inciting agents and to limit risks associated with future events of neutropenia.</p><p>Examples of monitoring schedules follow:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with uncomplicated, mild or moderate neutropenia, the ANC should be documented by serial complete blood counts (CBC). As an example, CBCs can be repeated weekly for the first two to four weeks, and again at three months:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If neutropenia resolves and the patient remains asymptomatic, there is no need for further follow-up. However, the patient should be re-evaluated urgently if fever or other infectious symptoms arise in the first year.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If mild neutropenia (&gt;1000 cells/ microL) persists, a CBC should be repeated every three to four months for the first year, and if stable, further evaluated only if the patient becomes symptomatic with fever, mouth sores, or other signs of a hematological disorder. The patient should be evaluated for fever or other infectious symptoms, but no other routine follow-up is required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For a patient with Duffy-null associated neutrophil count, no further monitoring is required, as described separately. (See <a class="local">'Normal variants &lt;1500/microL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follow-up of patients with other defined causes of neutropenia (eg, hematologic malignancy, rheumatologic disorder, splenomegaly) is guided by needs related to the underlying disease.</p><p></p><p class="headingAnchor" id="H2057044468"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120173.html" rel="external">"Society guideline links: Bone marrow failure syndromes"</a>.) </p><p class="headingAnchor" id="H1007004"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82906.html" rel="external">"Patient education: Neutropenia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1007010"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Neutropenia is defined as an absolute neutrophil count (ANC) &lt;1500 cells/microL (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>). (See <a class="local">'Definitions and normal values'</a> above.)</p><p></p><p class="bulletIndent1">When neutropenia is accompanied by anemia and/or thrombocytopenia, it is considered aplastic anemia (AA). Evaluation and diagnosis of AA are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – Initial evaluation of neutropenia includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – History of infections, prior neutropenia, other cytopenias, medications (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 1</a>), diet, alcohol use, and examination for liver disease, acute or chronic infection, or a rheumatologic disorder. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete blood count (CBC) </strong>– CBC with differential count and red blood cell (RBC) indices. (See <a class="local">'Complete blood count (CBC)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood smear</strong> – Assessment of neutrophil morphology and other lineages. (See <a class="local">'Peripheral blood smear'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – Further testing is guided by the duration, severity, and trajectory of neutropenia and findings from the initial evaluation. </p><p></p><p class="bulletIndent1">Scenarios include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutritional disorder</strong> – Patients with macrocytic RBC indices, hypersegmented neutrophils (<a class="graphic graphic_picture graphicRef70609" href="/z/d/graphic/70609.html" rel="external">picture 5</a>), macro-ovalocytes (<a class="graphic graphic_picture graphicRef74901" href="/z/d/graphic/74901.html" rel="external">picture 11</a>), history of gastrointestinal surgery, poor diet, alcohol use, or long-term veganism should be tested for RBC folate, vitamin B12, copper deficiency, and liver disease. (See <a class="local">'Nutritional deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected medications</strong> – Urgency of evaluation and management vary with the ANC:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Severe neutropenia</strong> (<strong>ANC &lt;1000 cells/microL)</strong> – Drugs associated with idiosyncratic reactions (<a class="graphic graphic_table graphicRef65507" href="/z/d/graphic/65507.html" rel="external">table 1</a>) should be discontinued immediately, if clinically feasible, and cytotoxic/immunosuppressive drugs should be withheld. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Moderate/mild neutropenia (ie, ≥1000 cells/microL)</strong> – Cytotoxic/immunosuppressive drugs should be withheld until the neutropenia improves, but it is not necessary to discontinue all suspected medications (eg, psychotropic or antiseizure medications).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infectious causes</strong> – Neutropenia can occur with viral hepatitis, HIV, or Epstein-Barr virus (EBV); bacterial, parasitic, and rickettsial infections. Observation and/or treatment with antimicrobials are appropriate. (See <a class="local">'Viral infection'</a> above.)  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rheumatologic condition</strong> – Evaluation of hematologic manifestations of rheumatologic conditions is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7512.html" rel="external">"Hematologic complications of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">"Hematologic manifestations of systemic lupus erythematosus", section on 'Neutropenia'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected hematologic malignancy</strong> – Bone marrow examination and/or flow cytometry should be performed for patients with unexplained splenomegaly, abnormal blood smear (eg, dysplastic features (<a class="graphic graphic_picture graphicRef85881" href="/z/d/graphic/85881.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">picture 3</a>), blasts (<a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">picture 6</a>), abnormal lymphoid cells (<a class="graphic graphic_picture graphicRef55986" href="/z/d/graphic/55986.html" rel="external">picture 7</a> and <a class="graphic graphic_picture graphicRef54469" href="/z/d/graphic/54469.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef102936" href="/z/d/graphic/102936.html" rel="external">picture 9</a> and <a class="graphic graphic_picture graphicRef69027" href="/z/d/graphic/69027.html" rel="external">picture 10</a>)), or other findings that suggest a leukemia or other hematologic malignancy, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal variant</strong> – Moderate neutropenia (eg, &gt;1000/microL) is more common in individuals of African descent, Sephardic Jews, West Indians, Yemenites, Greeks, and Arabs; this condition, formerly called "benign ethnic neutropenia", is not associated with increased risk for infections. Duffy null phenotype (Fy(a-b-)) supports the diagnosis. (See <a class="local">'Normal variants &lt;1500/microL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected familial disorder</strong> – Patients with a family history of unexplained neutropenia or characteristic skeletal, skin, or other characteristic somatic findings should be evaluated for an inherited disorder, as described separately. (See <a class="local">'Suspected congenital neutropenia'</a> above.)</p><p></p><p class="headingAnchor" id="H1933697341"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge the late Laurence A Boxer, MD, for his previous role as a section editor for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology Am Soc Hematol Educ Program 2012; 2012:485.</a></li><li><a class="nounderline abstract_t">Boxer LA. How to approach neutropenia. Hematology Am Soc Hematol Educ Program 2012; 2012:174.</a></li><li><a class="nounderline abstract_t">Andersen CL, Tesfa D, Siersma VD, et al. Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study. J Intern Med 2016; 279:566.</a></li><li><a class="nounderline abstract_t">Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146:486.</a></li><li><a class="nounderline abstract_t">Grann VR, Bowman N, Joseph C, et al. Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer 2008; 113:854.</a></li><li><a class="nounderline abstract_t">Wilson DB, Link DC, Mason PJ, Bessler M. Inherited bone marrow failure syndromes in adolescents and young adults. Ann Med 2014; 46:353.</a></li><li><a class="nounderline abstract_t">Merz LE, Achebe M. When non-Whiteness becomes a condition. Blood 2021; 137:13.</a></li><li><a class="nounderline abstract_t">Reich D, Nalls MA, Kao WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009; 5:e1000360.</a></li><li><a class="nounderline abstract_t">Reiner AP, Lettre G, Nalls MA, et al. Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT). PLoS Genet 2011; 7:e1002108.</a></li><li><a class="nounderline abstract_t">Auer PL, Teumer A, Schick U, et al. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. Nat Genet 2014; 46:629.</a></li><li><a class="nounderline abstract_t">Rosenthal EA, Makaryan V, Burt AA, et al. Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project. Genet Epidemiol 2016; 40:470.</a></li><li><a class="nounderline abstract_t">Makaryan V, Rosenthal EA, Bolyard AA, et al. TCIRG1-associated congenital neutropenia. Hum Mutat 2014; 35:824.</a></li></ol></div><div id="topicVersionRevision">Topic 90654 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233623" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Low blood counts: immune mediated, idiopathic, or myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233578" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : How to approach neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26791682" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404350" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18543314" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neutropenia in 6 ethnic groups from the Caribbean and the U.S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888387" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Inherited bone marrow failure syndromes in adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33181819" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : When non-Whiteness becomes a condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19180233" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21738479" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777453" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27229898" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753205" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : TCIRG1-associated congenital neutropenia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
